Literature DB >> 6279738

Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs.

S Alenius, M Berg, F Broberg, K Eklind, B Lindborg, B Oberg.   

Abstract

The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs. Foscarnet cream (3%) reduced both the cumulative vesicle score and the time for healing when HSV-1 strains C42 and 79 were tested. The application of foscarnet in cream form resulted in a dose-dependent reduction in skin virus titers and vesicle scores at concentrations ranging from 0.05% to 3%. Infections due to HSV-1 strain 79, but not those due to strain C42, were sensitive to treatment with 5% acyclovir in polyethylene glycol ointment. Topical application of 3% acyclovir in dimethyl sulfoxide on infections due to HSV-1 strain C42 resulted in a reduction in the skin virus titers, lesion scores, and the time for healing. Acyclovir, in both polyethylene glycol and dimethyl sulfoxide, was consistently less active than foscarnet cream in these animal experiments.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6279738     DOI: 10.1093/infdis/145.4.569

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  [Efficacy and tolerability of topical foscarnet sodium in treatment of herpes labialis. Results of post-marketing surveillance].

Authors:  G Gross; D Braun
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

2.  Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.

Authors:  D I Bernstein; C J Schleupner; T G Evans; D A Blumberg; Y Bryson; K Grafford; P Broberg; S Martin-Munley; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.

Authors:  E De Clercq; A Holý; I Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.

Authors:  S L Spruance; M B McKeough; J R Cardinal
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 7.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

8.  Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine.

Authors:  A C Ericson; A Larsson; F Y Aoki; W A Yisak; N G Johansson; B Oberg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 9.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

10.  9-(3,4-dihydroxybutyl)guanine, a new inhibitor of herpesvirus multiplication.

Authors:  A Larsson; B Oberg; S Alenius; C E Hagberg; N G Johansson; B Lindborg; G Stening
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.